Joseph Monahan - Feb 1, 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Scientific Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/3/2022, 03:49 PM
Previous filing
Sep 2, 2021
Next filing
Feb 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +1.05K +1.21% 87.7K Feb 1, 2022 Direct F1
holding ACRS Common Stock 193 Feb 1, 2022 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -1.05K -100% $0.00* 0 Feb 1, 2022 Common Stock 1.05K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 The shares underlying these restricted stock units vested on February 1, 2022.